Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms
Lung cancer continues to be a leading cause of cancer-related mortality worldwide, with survival rates stubbornly low despite significant advancements in conventional therapies. The limited effectiveness of traditional immunotherapies, particularly in advanced stages of the disease, highlights an ur...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1617352/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850114398834655232 |
|---|---|
| author | Alireza Pazoki Alireza Pazoki Sepehr Dadfar Sepehr Dadfar Atefe Alirezaee Atefe Alirezaee Valentyn Oksenych Dariush Haghmorad |
| author_facet | Alireza Pazoki Alireza Pazoki Sepehr Dadfar Sepehr Dadfar Atefe Alirezaee Atefe Alirezaee Valentyn Oksenych Dariush Haghmorad |
| author_sort | Alireza Pazoki |
| collection | DOAJ |
| description | Lung cancer continues to be a leading cause of cancer-related mortality worldwide, with survival rates stubbornly low despite significant advancements in conventional therapies. The limited effectiveness of traditional immunotherapies, particularly in advanced stages of the disease, highlights an urgent need for innovative treatment options. Cancer vaccines represent a promising Frontier in this battle, aiming to harness the power of the immune system to create lasting memory against tumor cells. This approach not only promotes tumor regression but also does so with minimal adverse effects. The death of tumor cells induced by these vaccines triggers a cascade of immune responses, activating functional T cells and sustaining the cancer-immunity cycle. Among emerging platforms, RNA-based vaccines have garnered particular attention for their rapid development potential, flexible design, and ability to induce robust cellular and humoral immunity. As a result, cancer vaccines—including RNA-based modalities—are increasingly viewed as a groundbreaking therapeutic strategy in the immunotherapy landscape for solid tumors. In this review, we examine recent advancements in lung cancer vaccines, focusing on antigen selection, innovative vaccine platforms and delivery strategies. Moreover, we provide a detailed analysis of ongoing and completed clinical trials, including targeted antigens, administration routes, and platforms used. Additionally, we discuss the potential benefits of combination therapies to enhance vaccine efficacy and address the limitations of these vaccines. Our goal is to provide a comprehensive overview of how these developments aim to overcome current treatment challenges and improve patient outcomes. |
| format | Article |
| id | doaj-art-16fc4adab1f54c99bf1d783766e8bdb7 |
| institution | OA Journals |
| issn | 2296-4185 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj-art-16fc4adab1f54c99bf1d783766e8bdb72025-08-20T02:36:53ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852025-06-011310.3389/fbioe.2025.16173521617352Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platformsAlireza Pazoki0Alireza Pazoki1Sepehr Dadfar2Sepehr Dadfar3Atefe Alirezaee4Atefe Alirezaee5Valentyn Oksenych6Dariush Haghmorad7Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan, IranDepartment of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan, IranImmunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, IranPediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, IranBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, IranLung cancer continues to be a leading cause of cancer-related mortality worldwide, with survival rates stubbornly low despite significant advancements in conventional therapies. The limited effectiveness of traditional immunotherapies, particularly in advanced stages of the disease, highlights an urgent need for innovative treatment options. Cancer vaccines represent a promising Frontier in this battle, aiming to harness the power of the immune system to create lasting memory against tumor cells. This approach not only promotes tumor regression but also does so with minimal adverse effects. The death of tumor cells induced by these vaccines triggers a cascade of immune responses, activating functional T cells and sustaining the cancer-immunity cycle. Among emerging platforms, RNA-based vaccines have garnered particular attention for their rapid development potential, flexible design, and ability to induce robust cellular and humoral immunity. As a result, cancer vaccines—including RNA-based modalities—are increasingly viewed as a groundbreaking therapeutic strategy in the immunotherapy landscape for solid tumors. In this review, we examine recent advancements in lung cancer vaccines, focusing on antigen selection, innovative vaccine platforms and delivery strategies. Moreover, we provide a detailed analysis of ongoing and completed clinical trials, including targeted antigens, administration routes, and platforms used. Additionally, we discuss the potential benefits of combination therapies to enhance vaccine efficacy and address the limitations of these vaccines. Our goal is to provide a comprehensive overview of how these developments aim to overcome current treatment challenges and improve patient outcomes.https://www.frontiersin.org/articles/10.3389/fbioe.2025.1617352/fulllung cancerimmunotherapycancer vaccinestherapeutic vaccinescancer therapy |
| spellingShingle | Alireza Pazoki Alireza Pazoki Sepehr Dadfar Sepehr Dadfar Atefe Alirezaee Atefe Alirezaee Valentyn Oksenych Dariush Haghmorad Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms Frontiers in Bioengineering and Biotechnology lung cancer immunotherapy cancer vaccines therapeutic vaccines cancer therapy |
| title | Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms |
| title_full | Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms |
| title_fullStr | Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms |
| title_full_unstemmed | Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms |
| title_short | Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms |
| title_sort | lung cancer vaccine strategies exploring the spectrum from traditional to rna based platforms |
| topic | lung cancer immunotherapy cancer vaccines therapeutic vaccines cancer therapy |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1617352/full |
| work_keys_str_mv | AT alirezapazoki lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT alirezapazoki lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT sepehrdadfar lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT sepehrdadfar lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT atefealirezaee lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT atefealirezaee lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT valentynoksenych lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms AT dariushhaghmorad lungcancervaccinestrategiesexploringthespectrumfromtraditionaltornabasedplatforms |